Completed

MultiPAMSEvaluation and Validation of a Multimodal MRI Neuroimaging Method: Application to Differential Diagnosis and Disease Progression in Parkinsonian Syndromes

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

MRI acquisition

+ behavioral evaluations

OtherBehavioral
Who is being recruted

Synucleinopathies+9

+ Autonomic Nervous System Diseases

+ Basal Ganglia Diseases

From 18 to 80 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: January 2013
See protocol details

Summary

Principal SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 24, 2013

Actual date on which the first participant was enrolled.

30 patients with PD, 30 patients with MSA and 30 healthy controls will be examined in a 3Tesla MRI. The aim of our project is to demonstrate that our multimodal MRI method can discriminate both diseases with a similar clinical presentation and monitor the progress of the disease. CIC's expertise in recruitment and assessment of patients, and the powers of the INSERM U825 in terms of development and processing in neuroimaging guarantee the feasibility of the project and its successful completion.

Official TitleEvaluation and Validation of a Multimodal MRI Neuroimaging Method: Application to Differential Diagnosis and Disease Progression in Parkinsonian Syndromes
NCT02428816
Principal SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

94 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

SynucleinopathiesAutonomic Nervous System DiseasesBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesMovement DisordersNervous System DiseasesParkinson DiseaseMultiple System AtrophyNeurodegenerative DiseasesParkinsonian DisordersPrimary Dysautonomias

Criteria

6 inclusion criteria required to participate
informed consent signed
right handed patients
Mini Mental Score > 22
no other neurological disease than Parkinson's Disease (PD) or Multiple System Atrophy (MSA)
Show More Criteria
6 exclusion criteria prevent from participating
claustrophobia
contraindications to MRI (cardiac or auditive prothesis, pacemakers, cerebral clip, stimulating electrodes)
pregnant women
major neuropsychiatric disease
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit

Group II

Experimental
Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)

Group III

Experimental
Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Inserm Umr 825

Toulouse, FranceOpen Inserm Umr 825 in Google Maps
CompletedOne Study Center